Foghorn raises $120m in its IPO; The Cambridge biotech is working on a system to regulate genes to treat cancer.
The Cambridge company is working on a system to regulate genes to treat diseases.
Stock in Foghorn Therapeutics Inc. was up about 13 percent Friday at the end of its first day of trading on the Nasdaq exchange, after the Cambridge biotech startup raised $120 million in its initial public offering.
The biotech on Thursday said it would offer 7.5 million shares at $16 apiece, the midpoint of its expected range of $15 to $17. The stock is trading ...